selected scholarly activity
-
journal articles
- Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.. Journal of Clinical Oncology. 42:4271-4281. 2024
- Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study. European Journal of Cancer. 195:113342-113342. 2023
- Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial.. Journal of Clinical Oncology. 39:240-240. 2021
- Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. European urology oncology. 4:93-101. 2021
- Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. European Urology. 75:853-860. 2019
- Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection. Investigative Urology. 199:655-662. 2018
- 117 Validation of a mRNA-based urine test for bladder cancer detection in patients with hematuria. European Urology Open Science. 16:e190-e191. 2017
- 119 Performance characteristics of a mRNA-based urine test for the detection of bladder cancer recurrence. European Urology Open Science. 16:e193-e194. 2017
- Use of a Multitarget Fluorescence In Situ Hybridization Assay to Diagnose Bladder Cancer in Patients With Hematuria. Investigative Urology. 176:44-47. 2006